Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07933848
PHASE1

A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function. This study is seeking participants who: * Have moderate or severe renal impairment or * Healthy people with normal kidney function All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function. Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.

Official title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-11-17

Completion Date

2028-05-27

Last Updated

2026-11-12

Healthy Volunteers

Yes

Interventions

DRUG

Prifetrastat

Prifetrastat administered by mouth as a single dose.

Locations (3)

Floridian Clinical Research

Miami Lakes, Florida, United States

Genesis Clinical Research, LLC

Tampa, Florida, United States

Nucleus Network Minneapolis

Saint Paul, Minnesota, United States